-
Siolta Therapeutics Raises $12 Million in Series C Financing for Clinical Development
3.13.2024WilmerHale represented Siolta Therapeutics, Inc., a biotech company developing live biotherapeutics that target the core drivers of disease, in its $12 million Series C Preferred Stock financing.
-
WilmerHale Advises Georgiamune on $75M Series A Financing
8.14.2023On August 9, 2023, Georgiamune Inc., a privately held, clinical stage biotechnology company, announced the clearance of its Investigational New Drug application by the US Food and Drug Administration for GIM-122, a dual-functioning monoclonal antibody.
-
WilmerHale Advises Wellington Management in MBX Biosciences’ $115M Series B Financing
12.8.2022On November 14, MBX Biosciences, a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, announced the closing of a $115 million Series B financing round led by Wellington Management, which was represented by WilmerHale.
-
WilmerHale Advises Visterra in $46.7M Series C Financing
10.17.2017Visterra, Inc., a clinical-stage biotechnology company that uses its novel Hierotope® platform to identify unique disease targets, announced that it has completed a Series C financing round raising a total of $46.7 million, including a new extension totaling $23.6 million.
-
WilmerHale Reps Disarm Therapeutics in $30M Series A Financing
10.5.2017Disarm Therapeutics, a new biotechnology company developing therapeutics to treat patients with neurological diseases by preventing axonal degeneration, announced the recent completion of a $30 million Series A financing.
-
Cool Planet Closes on Nearly $20M to Fund Commercialization of Engineered Biocarbon Products
4.25.2017WilmerHale counseled agriculture technology company Cool Planet in the closing of a $19.3 million Series A financing to commercialize its Cool Terra and Cool Fauna engineered biocarbon products.
-
M&A: The Last Refuge For Biotechs Seeking Funding
3.14.2016WilmerHale's Life Sciences Group Co-Chairs Belinda Juran and Stuart Falber are interviewed by MedCity News—published by Breaking Media which, earlier this year, ranked the firm among the top three Best Life Sciences Law Firms for 2016 in its inaugural Life Science Index.
-
LMG Life Sciences Honors Firm, Attorneys with Top Rankings for Third Consecutive Year
8.28.2014The 2014 edition of LMG Life Sciences has been released, and it includes the recognition of nine WilmerHale practice areas and 17 attorneys.
